Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

Congratulations to Bristol Myers Squibb on winning the 2025 Gold Alexander Hamilton Award in Working Capital Management!

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

An ADR is created when a bank buys shares of a foreign company outside the United States and issues a security representing shares of that company. Priced in U.S. dollars, these ADR shares trade just ...

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bob Myers said what everyone's been thinking about Stephen A. Smith over the last few weeks.

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...